Added to YB: 2024-07-15
Pitch date: 2024-07-15
VRCI.L [bullish]
Verici Dx plc
-97.08%
current return
Author Info
No bio for this author
Company Info
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States.
Market Cap
GBP 7.0M
Pitch Price
GBP 0.07
Price Target
0.20 (+9900%)
Dividend
N/A
EV/EBITDA
-0.60
P/E
-0.35
EV/Sales
1.04
Sector
Biotechnology
Category
growth
Verici Dx - $VRCI.L
VRCI.L: Kidney transplant diagnostics firm. H1'24 rev $3.3m vs $1.0m FY23. $2.8m/$5.0m received from TMO deal. 20p PT. Est. 90% margins, $9m fixed costs. $7.5m/$13.0m rev 2024/25, $1.3m EBITDA 2025. $7.0m cash. Protega study H1'25. Tutivia sold in US. Seeking Medicare cover ($2,650/test). RNA signature tech: 79% PPV for Tutivia.
Read full article (2 min)